Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 4
1973 2
1999 1
2001 3
2002 8
2003 9
2004 10
2005 9
2006 12
2007 8
2008 18
2009 13
2010 15
2011 17
2012 26
2013 24
2014 32
2015 27
2016 22
2017 43
2018 51
2019 43
2020 67
2021 82
2022 61
2023 59
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

628 results

Results by year

Filters applied: . Clear all
Page 1
The use of intravascular contrast media in patients with impaired kidney function - joint clinical practice position statement of the Polish Society of Nephrology and the Polish Medical Society of Radiology.
Chmielewski M, Serafin Z, Kamińska D, Skrobisz K, Kozak O, Olczyk P, Rutkowski P, Adamczak M, Szurowska E, Krajewska M. Chmielewski M, et al. Among authors: rutkowski p. Pol J Radiol. 2024 Mar 21;89:e161-e171. doi: 10.5114/pjr.2024.136950. eCollection 2024. Pol J Radiol. 2024. PMID: 38550960 Free PMC article. Review.
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.
Stassen RC, Maas CCHM, van der Veldt AAM, Lo SN, Saw RPM, Varey AHR, Scolyer RA, Long GV, Thompson JF, Rutkowski P, Keilholz U, van Akkooi ACJ, Verhoef C, van Klaveren D, Grünhagen DJ. Stassen RC, et al. Among authors: rutkowski p. Lancet Oncol. 2024 Apr;25(4):509-517. doi: 10.1016/S1470-2045(24)00076-7. Lancet Oncol. 2024. PMID: 38547894
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak A, Del Vecchio M, de la Cruz-Merino L, Mackiewicz J, Sileni VC, Kirkwood JM, Robert C, Grob JJ, Dummer R, Carlino MS, Zhao Y, Kalabis M, Krepler C, Eggermont A, Scolyer RA. Schadendorf D, et al. Among authors: rutkowski p. J Immunother Cancer. 2024 Mar 13;12(3):e007501. doi: 10.1136/jitc-2023-007501. J Immunother Cancer. 2024. PMID: 38485189 Free PMC article. Clinical Trial.
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Luke JJ, et al. Among authors: rutkowski p. J Clin Oncol. 2024 Mar 7:JCO2302355. doi: 10.1200/JCO.23.02355. Online ahead of print. J Clin Oncol. 2024. PMID: 38452313
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhrer E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Kennedy OJ, et al. Among authors: rutkowski p. Eur J Cancer. 2024 Apr;201:113585. doi: 10.1016/j.ejca.2024.113585. Epub 2024 Feb 1. Eur J Cancer. 2024. PMID: 38402687 Clinical Trial.
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Synoradzki KJ, Paduszyńska N, Solnik M, Toro MD, Bilmin K, Bylina E, Rutkowski P, Yousef YA, Bucolo C, Zweifel SA, Reibaldi M, Fiedorowicz M, Czarnecka AM. Synoradzki KJ, et al. Among authors: rutkowski p. Curr Oncol. 2024 Feb 1;31(2):778-800. doi: 10.3390/curroncol31020058. Curr Oncol. 2024. PMID: 38392052 Free PMC article. Review.
628 results